{"prompt": "['NCT03915860', 'GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 1 of 88', 'CLINICAL TRIAL PROTOCOL', 'PROTOCOL NUMBER: RD.06.SPR.118295', 'CONFIDENTIAL', 'This document contains confidential, proprietary information', 'All the information provided to the Investigator and his/her staff and all data obtained through this', 'GALDERMA clinical trial protocol are confidential. The Sponsor reserves all proprietary rights.', 'No information may be disclosed to any third party without prior written consent from', 'GALDERMA.']['GALDERMA R&D', 'RD.06.SPR.11829. Protocol V02 04Jun2019', 'Page 2 of 88', 'TITLE PAGE', 'Title', 'A Multi-Center Study to evaluate Subject Reported Outcomes with use of Trifarotene 50 g/g cream in the', 'treatment of moderate facial and truncal acne vulgaris', 'Project Name or CD number:', 'Project Number:', 'Clinical Trial Phase:', 'CD5789', '02232', 'Illb', 'IND Number 111091', 'SPONSOR:', 'Name:', 'GALDERMA RESEARCH & DEVELOPMENT, LLC', 'Address:', '14501 North Freeway', 'Fort Worth, TX 76177', 'Telephone:', '(817) 961-5000', 'For any safety questions, please contact the Clinical Safety Officer (CSO) using the contact', 'details provided in Section 7.2.2.2.2.', 'For any medical questions related to the clinical trial protocol, please contact the Medical Expert', 'using the contact details below:', 'Name and Title:', 'PPD', 'MD, Medical Expert', 'Address:', 'Galderma R&D, LLC', '14501 North Freeway', 'Fort Worth, TX 76177', 'USA', 'Telephone (mobile):', 'PPD', 'Fax:', 'PPD', 'E-mail:', 'PPD']['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 3 of 88', 'This clinical trial will be performed in compliance with applicable regulatory requirements and', 'Good Clinical Practice (GCP). This clinical trial protocol follows guidelines outlined by the', 'International Conference on Harmonisation (ICH) and the Galderma template.']\n\n###\n\n", "completion": "END"}